User:Mr. Ibrahem/Nirmatrelvir/ritonavir

Nirmatrelvir/ritonavir (NMV-r), sold under the brand name Paxlovid, is two medications packaged together and used to treat COVID-19. It is used within 5 days of the start of symptoms, in people who do not require supplemental oxygen, but are at high risk of developing severe COVID-19. It is taken by mouth.

Common side effects include taste disturbances, diarrhea, high blood pressure, and muscle pains. Safety in pregnancy is unclear. It should not be used in people with severe liver or kidney problems. It has a number of medication interactions, including with hormonal birth control. It is contains nirmatrelvir, a SARS-CoV-2 main protease inhibitor and ritonavir, a CYP3A inhibitor.

The combination was approved for medical use in the United Kingdom in December of 2021. It also received emergency use authorization in the United States that month. In 2021 the United States government bought 10 million courses of treatment at 530 USD each, which it will be providing at no cost to Americans. Approval occurred in the United States in 2023. In Canada it costs about 1,400 CAD per course as of 2024.